Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
From Pfizer Inc.
Via Business Wire
Tickers PFE
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries
From Pfizer Inc.
Via Business Wire
Tickers PFE
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Declares First-Quarter 2023 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma
From Pfizer Inc.
Via Business Wire
Tickers PFE
PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.